Dr. Robert Xin joined Turning Point as senior vice president of clinical development in January 2019. He has more than 20 years of oncology drug discovery and clinical development experience in biotech and large biopharma companies for indications in solid tumors and hematologic malignancies, in a variety of therapeutic modalities. For the past six years, he has served in positions of increasing leadership responsibility at Pfizer, most recently as interim vice president of oncology clinical development. Before Pfizer, Dr. Xin served for seven years at Roche/Genentech in senior oncology clinical development roles. His early career experience includes drug discovery, development and translational medicine roles at Chiron, Eli Lilly and Sugen. His extensive experience includes multiple successful drug approvals including Zelboraf®, Gazyva®, Erivedge®, Rituxan®, and Sutent®, companion diagnostic development, regulatory and clinical strategy, and organizational leadership. Dr. Xin earned his M.D. and M.S. in pharmacology from the Zhejiang University School of Medicine in China. In addition, he earned a Ph.D. in cell and molecular physiology from the University of North Carolina at Chapel Hill School of Medicine.